MUMBAI: Shares of pharmaceutical major Cipla Ltd on Thursday gained as much as 16%, after the company received approval from the US Food and Drug Administration (USFDA) for its generic version of Proventil HFA Inhalation Aerosol drug.
At 10.45 am, the stock traded at ₹585.60, up 14.15% from its previous close, while the benchmark Sensex rose 2.93% and BSE Healthcare index advanced 4.74%.
In an exchange filing, Cipla said it has received "final approval for its abbreviated new drug application (ANDA) for Albuterol Sulfate Inhalation Aerosol 90mcg (base)/actuation from the USFDA." The drug is the first AB-rated generic therapeutic equivalent version of Merck Sharp & Dohme Corp's Proventil HFA Inhalation Aerosol.
Read more on livemint.com